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Local delivery of novel MRTF/SRF 
inhibitors prevents scar tissue 
formation in a preclinical model of 
fibrosis
Cynthia Yu-Wai-Man1,2,3, Bradley Spencer-Dene4, Richard M. H. Lee2, Kim Hutchings5, Erika 
M. Lisabeth6, Richard Treisman3, Maryse Bailly  1, Scott D. Larsen5, Richard R. Neubig6 & 
Peng T. Khaw2
The myocardin-related transcription factor/serum response factor (MRTF/SRF) pathway represents a 
promising therapeutic target to prevent fibrosis. We have tested the effects of new pharmacological 
inhibitors of MRTF/SRF signalling in a preclinical model of fibrosis. CCG-222740, a novel MRTF/SRF 
inhibitor, markedly decreased SRF reporter gene activity and showed a greater inhibitory effect on 
MRTF/SRF target genes than the previously described MRTF-A inhibitor CCG-203971. CCG-222740 was 
also five times more potent, with an IC50 of 5 μM, in a fibroblast-mediated collagen contraction assay, 
was less cytotoxic, and a more potent inhibitor of alpha-smooth muscle actin protein expression than 
CCG-203971. Local delivery of CCG-222740 and CCG-203971 in a validated and clinically relevant rabbit 
model of scar tissue formation after glaucoma filtration surgery increased the long-term success of the 
surgery by 67% (P < 0.0005) and 33% (P < 0.01), respectively, and significantly decreased fibrosis and 
scarring histologically. Unlike mitomycin-C, neither CCG-222740 nor CCG-203971 caused any detectable 
epithelial toxicity or systemic side effects with very low drug levels measured in the aqueous, vitreous, 
and serum. We conclude that inhibitors of MRTF/SRF-regulated gene transcription such as CCG-222740, 
potentially represent a new therapeutic strategy to prevent scar tissue formation in the eye and other 
tissues.
Fibrosis represents one of the largest unmet needs in clinical medicine and accounts for over 40% of all deaths. 
In the eye, fibrosis is also linked to the pathogenesis or failure of treatment of most blinding diseases worldwide. 
Glaucoma is the leading cause of irreversible blindness and its prevalence is estimated to reach 79.6 million 
people by 2020, with more than 11 million individuals suffering from bilateral blindness1. Wound contraction 
and scarring are the principal causes of blockage of aqueous flow at the drainage site in glaucoma filtration sur-
gery2. Current clinical practice to counteract these phenomena uses the cytotoxic antimetabolites mitomycin-C 
(MMC) and 5-fluorouracil (5-FU). These non-specific agents cause widespread cell death and apoptosis3 and have 
long-standing effects on cell proliferation4. Their use is also associated with potentially blinding complications, 
such as tissue breakdown and infection5, 6. Alternative agents with more targeted physiological effects and less 
cytotoxicity are thus needed.
SRF is a ubiquitous transcription factor that was first identified as a regulator of growth-factor regulated 
immediate-early genes. Working in partnership with its coactivators MRTF-A and MRTF-B, SRF regulates the 
majority of cytoskeletal genes7, 8, including many that are involved in fibrosis9–11. The activity of MRTF-A and 
MRTF-B, which bind G-actin through N-terminal RPEL motifs, responds to variations in the cellular concen-
tration of G-actin induced by Rho GTPase signalling12, 13. Given the potential connection between MRTF/SRF 
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signalling and fibrosis, there has been considerable interest in exploiting it as a route to clinical intervention and 
studies have previously been undertaken to evaluate this in mouse models of vascular9, skin10, and lung fibrosis11.
We previously sought to identify inhibitors of MRTF-SRF signalling by high-throughput screening using an 
MRTF-SRF reporter gene that selectively responds to RhoA-induced gene transcription14. Using this approach, 
we identified CCG-1423 as a potent inhibitor of RhoA-stimulated MRTF/SRF gene transcription15. More recently, 
we have also optimised a second generation inhibitor, CCG-203971, which is less cytotoxic than CCG-142316, 17. 
The mechanism of action of these compounds remains unclear: it has been proposed that CCG-1423 is an inhib-
itor of MICAL-2, a member of the MICAL family of actin-binding mono-oxygenases18, or that it acts directly on 
MRTF-A and other RPEL-family of proteins to prevent the nuclear import of MRTF-A19.
Here we investigate the potential local application of MRTF/SRF inhibitors to counter fibrosis in the eye and 
other tissues20, 21. We show that a novel second-generation MRTF/SRF inhibitor, CCG-222740, exerts a greater 
inhibitory effect on MRTF/SRF target genes than CCG-203971. CCG-222740 is also more potent at preventing 
alpha-smooth muscle actin protein expression, is less cytotoxic, and effectively prevents scar tissue formation in 
a preclinical model of fibrosis.
Results
CCG-222740 is a novel and effective MRTF/SRF pathway inhibitor. We tested two candidate 
MRTF/SRF pathway inhibitors, CCG-222740 and CCG-203971, using a functional three-dimensional fibro-
blast-populated collagen contraction assay. We chose this assay as it has been shown to be a good in vitro model 
to study tissue contraction22–24. CCG-222740 and CCG-203971 both decreased collagen matrix contraction in 
a concentration-dependent manner but CCG-222740 was five times more potent than CCG-203971 in human 
conjunctival fibroblasts [IC50 = 5 μM compared to 25 μM] (Fig. 1A and B). We also confirmed our results in rabbit 
conjunctival fibroblasts, where CCG-222740 was similarly more effective at decreasing collagen matrix contrac-
tion than CCG-203971 (Fig. 2A and B). In addition, CCG-222740 was less cytotoxic than CCG-203971 with a cell 
viability of 100% at 10 μM, 88% at 30 μM, and 85% at 100 μM (Fig. 1C).
We next compared how CCG-222740 and CCG-203971 affect the activity of an SRF reporter gene in trans-
fected cells. Both compounds showed similar activity, with almost 100% inhibition of baseline reporter activity 
(Figs 1D and 2E,F). However, examination of endogenous gene expression revealed that CCG-222740 was a more 
potent inhibitor of expression for two MRTF/SRF target genes classically linked to fibrosis (ACTA2, coding for 
alpha-smooth muscle actin – αSMA; and CTGF, coding for Connective Tissue Growth Factor)25, 26 (Fig. 1E–H). 
CCG-222740 also decreased ACTA2 gene expression to a greater extent than CCG-203971 in rabbit conjunctival 
fibroblasts (Fig. 2C and D).
We further tested the effects of the inhibitors on αSMA protein expression and found that CCG-222740 
was more potent than CCG-203971 at decreasing αSMA protein expression in human conjunctival fibroblasts 
(Fig. 3D). Human conjunctival fibroblasts grown in 10% serum contain a small subpopulation of fibroblasts 
with prominent αSMA-positive stress fibres (about 20%). CCG-222740 treatment decreased the percentage of 
αSMA-positive fibroblasts from 24.5% to 9.0% (P < 0.01) and 2.2% (P < 0.001) at 10 μM and 25 μM, respectively 
(Fig. 3A and C). CCG-203971 treatment only decreased the percentage of αSMA-positive fibroblasts from 24.5% 
to 17.0% (P < 0.05) and 8.6% (P < 0.01) at 10 μM and 25 μM, respectively (Fig. 3B and C).
CCG-222740 and CCG-203971 increase the long-term success of surgery in a preclinical model 
of fibrosis. We next studied the effects of CCG-222740 and CCG-203971 using a validated and clinically rel-
evant animal model of wound healing after glaucoma filtration surgery27, 28. Subconjunctival scarring after glau-
coma filtration surgery was chosen as it is one of the most aggressive models of scar tissue formation, and failure 
of surgery is due to excessive scarring. This animal model is also validated for scar tissue formation in humans and 
agents that have reduced scarring in the rabbit have been shown to be effective in humans in clinical trials29–31.
Drugs are rapidly cleared from the subconjunctival space after glaucoma filtration surgery32, and we therefore 
adopted a dosing strategy in which subconjunctival injections into the bleb were administered daily for the first 
nine days followed by twice weekly injections for three weeks. This protocol, previously used in the rabbit model 
for anti-scarring inhibitors requiring continuous exposure4, maximises local availability of the drug at the critical 
time of postoperative wound repair, and maintains availability during the later stages of wound remodelling33 (see 
Materials and Methods). CCG-222740 and CCG-203971 were used at concentrations similar to the serum con-
centrations resulting from systemic administration (100 mg/kg) in mouse models of dermal and lung fibrosis10, 11.
A bleb arises when a filtration cannula is inserted into the eye during the surgery and drains aqueous fluid 
from the anterior chamber of the eye to under the conjunctival tissue, forming a visible raised collection of fluid. 
We used bleb survival (fluid present under the conjunctival tissue) as our primary end-point as this is indicative 
of a significant reduction in scar tissue formation and the long-term opening of the pathway created during the 
surgery. A bleb is considered to have failed when it becomes flat, scarred, vascularised and is associated with a 
deep anterior chamber. At day 30, the blebs that survived after treatment with CCG-222740 or CCG-203971 
remained diffusely elevated whereas all the blebs in animals treated with vehicle control became flat, scarred and 
vascularised (Fig. 4A). CCG-222740 and CCG-203971 treatments increased the long-term success of the surgery 
by 67% (P < 0.0005) and 33% (P < 0.01), respectively, compared to vehicle control (Fig. 4B). When compared 
to the cytotoxic antimetabolite, mitomycin C (MMC), CCG-222740 had equally good surgical outcomes with 
the blebs failing at a mean of 28.5 days (SEM 1.0) with CCG-222740 and 28.8 days (SEM 1.2) with MMC. CCG-
203971 had a worse surgical outcome compared to CCG-222740 with the blebs failing earlier at 22.5 days (SEM 
2.7), but it was better than the vehicle control-treated rabbits where all the blebs failed before day 30 and the mean 
failure day was 14 days (SEM 1.0).
We used intraocular pressure (IOP) survival and bleb area as secondary end-points in the study. IOP is consid-
ered to have failed when there is an indefinite return to baseline level or greater. IOP was significantly lower in the 
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MMC-treated group (P < 0.002) compared to vehicle control. IOP also remained consistently lower than baseline 
measurements in the groups treated with CCG-222740 (P < 0.0005) and CCG-203971 (P < 0.05) (Fig. 4C). In 
addition, the CCG-222740-treated group had significantly larger bleb area (P < 0.02) compared to vehicle con-
trol (Fig. 4D). The bleb area was also significantly larger in the group treated with MMC (P < 0.02) compared to 
Figure 1. CCG-222740 is an effective MRTF/SRF pathway inhibitor. (A,B) Human conjunctival fibroblasts 
were seeded in collagen type I matrix and cultured for 7 days with or without CCG-222740 and CCG-203971 
at the indicated concentrations. Each experiment used triplicate gels per condition, and the experiment was 
repeated three times; (C) Effect of CCG-222740 and CCG-203971 in cell proliferation, assessed using CellTiter 
96 Aqueous one solution assay. Results are mean ± SEM for triplicate experiments; (D) Human conjunctival 
fibroblasts were transfected with the SRF reporter gene 3DA.Luc, serum-starved, and treated with different 
concentrations of CCG-222740 or CCG-203971 or 0.1% DMSO control for 24 hours. Results represent 
mean ± SEM for triplicate experiments; (E,F,G,H) Human conjunctival fibroblasts were treated with different 
concentrations of CCG-222740 or CCG-203971 or 0.1% DMSO control in 10% FCS + DMEM for 24 hours, 
and MRTF/SRF target gene expression assessed by qRT-PCR. Results represent mean ± SEM for triplicate 
experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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vehicle control. There were, however, no statistically significant differences in the bleb area between the CCG-
203971-treated group and vehicle control. Taken together, these results show that inhibition of MRTF/SRF sig-
nalling is effective at increasing the long-term success of surgery in this preclinical model of fibrosis, and that 
CCG-222740 is more effective than CCG-203971.
Local delivery of CCG-222740 or CCG-203971 prevents scar tissue formation. We further eval-
uated the histologic differences after local delivery of CCG-222740 and CCG-203971. The white filtration tube 
Figure 2. CCG-222740 is more effective than CCG-203971 in rabbit conjunctival fibroblasts. (A,B) Rabbit 
conjunctival fibroblasts were seeded in collagen type I matrix and cultured for 7 days as in Fig. 1A and B. 
(C,D) Analysis of ACTA2 gene expression in rabbit conjunctival fibroblasts was analysed by qRT-PCR as in 
Fig. 1E and F. Results represent mean ± SEM for triplicate experiments. *P < 0.05; **P < 0.01. (E) Rabbit 
conjunctival fibroblasts were transfected with the SRF reporter 3DA.luc, serum-starved, and treated with 
different concentrations of CCG-222740 or CCG-203971 or 0.1% DMSO control for 24 hours. Results represent 
mean ± SEM for triplicate experiments; (F) HEK293 cells were transfected with the SRF reporter SRE.L luc 
and treated as in (E). Results represent mean ± SEM for triplicate experiments; (G) HEK293 cell viability in the 
presence of CCG-222740 or CCG-203971 was measured using the WST-1 assay. Results represent mean ± SEM 
for triplicate experiments.
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was used as landmark and the plane of sectioning of the bleb area was performed 2 mm from the tube (black line 
in Fig. 5). Grading was performed using a modified system originally described by Shah et al.34. The left operated 
eyes were compared to the right non-operated eyes that were used as controls for the appearance of normal con-
junctival tissue. The sections were graded using a scale of −4 to +4 (0 = same as control eye; 1 = 1–25% difference 
from control eye; 2 = 26–50% difference from control eye; 3 = 51–75% difference from control eye; 4 = >75% 
difference from control eye; prefix+, more than; prefix−, less than). Analysis was performed using the mean 
results in each treatment group.
There were some variations between conjunctival sections from different rabbits but a significant decrease 
in scar tissue formation was noted after treatment with CCG-222740 (P < 0.03) or CCG-203971 (P < 0.05), 
compared to vehicle control (Fig. 5A and E). Total cellularity also remained significantly increased in the 
vehicle-treated group compared to the CCG-222740-treated (P < 0.005) or CCG-203971-treated groups 
(P < 0.05) (Fig. 5B and F). In addition, CCG-222740 (P < 0.02) or CCG-203971 treatments (P < 0.05) significantly 
decreased the expression of αSMA by cells, suggesting the presence of fewer myofibroblasts (Fig. 5C and G). The 
presence of newly laid extracellular matrix and collagen was also present to a greater degree in the vehicle-treated 
group compared to the CCG-222740-treated (P < 0.005) or CCG-203971-treated groups (P < 0.02) (Fig. 5D and 
H).
CCG-222740 and CCG-203971 do not cause any detectable local toxicity or systemic side 
effects. We also assessed the local toxicity and pharmacokinetics of CCG-222740 and CCG-203971. MMC 
exerts its anti-scarring effects by arresting the cell cycle and causing widespread apoptosis of fibroblasts in the 
conjunctiva3. However, the local toxicity of MMC is caused by the concurrent damage to the conjunctival epithe-
lial layer leading to tissue breakdown and severe infection. MMC treatment led to characteristic thin and avascu-
lar blebs and caused disruption of the epithelial cell layer (Fig. 6A). We further stained the tissue sections for the 
Ki67 protein, which is a cellular marker of proliferation, and found that MMC treatment markedly reduced the 
number of Ki67 positive cells in the conjunctival epithelium (Fig. 6B). In contrast, CCG-222740 and CCG-203971 
Figure 3. CCG-222740 is more potent than CCG-203971 at decreasing αSMA protein expression. (A,B) 
Human conjunctival fibroblasts were treated for 48 hours with 10 or 25 μM of CCG-222740 or CCG-203971 
or 0.1% DMSO control in DMEM +10% FCS. The fibroblasts were stained with Cy3-labelled alpha smooth 
muscle actin antibody, phalloidin and DAPI. Scale bar = 30 μm; (C) Fibroblasts that are positive for αSMA 
clearly display αSMA-positive stress fibres, which were quantified visually from three random fields of view per 
treatment group. Results represent mean ± SEM for triplicate experiments. *P < 0.05; **P < 0.01; ***P < 0.001. 
(D) Western blot analysis of αSMA protein expression in human conjunctival fibroblasts treated with CCG-
222740 or CCG-203971 as in (A,B). Cropped blots are displayed and the full-length blots are shown in 
Supplementary Figure S1.
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treatments did not cause any detectable local toxicity with an intact and healthy-looking conjunctival epithelium 
that was similar to the non-operated eyes, and with normal Ki67 positive cells in the conjunctival epithelium 
(Fig. 6A and B). There were also no signs of corneal or conjunctival toxicities or anterior chamber inflammation 
noted after local delivery of CCG-222740 or CCG-203971. Local tissue reaction to treatment was further assessed 
by conjunctival vascularity. MMC treatment led to thin avascular blebs but there were no abnormalities in con-
junctival vascularity noted in the CCG-222740 and CCG-203971-treated groups (Fig. 6C).
In addition, the rabbits were carefully monitored throughout the study and none of them showed any signs of 
systemic toxicity after local delivery of CCG-222740 or CCG-203971 to the conjunctiva. We also tested the con-
centrations of CCG-222740 and CCG-203971 at day 30 in the aqueous, vitreous, and serum of the rabbits. Levels 
of CCG-222740 and CCG-203971 were very low and below 20 nM in all serum, aqueous, and vitreous samples 
collected 48 hours after the last dose was administered by local subconjunctival delivery.
Figure 4. CCG-222740 and CCG-203971 increase the long-term success of surgery in a preclinical model 
of fibrosis. (A) Morphology of blebs after surgery and treatment with CCG-222740, CCG-203071, MMC or 
vehicle. Arrows indicate bleb edges. (B) Kaplan-Meier graph comparing the bleb survival between CCG-222740 
[N = 6], CCG-203971 [N = 6], MMC [N = 6], and vehicle control [N = 6]. CCG-222740 and CCG-203971 
treatments significantly increased bleb survival by 67% (P < 0.0005) and 33% (P < 0.01), respectively, compared 
to vehicle control. (C) Intraocular pressure (IOP) survival, i.e. when the intraocular pressure remains below 
the baseline IOP measurement. CCG-222740 and CCG-203971 treatments increased IOP survival by 67% 
(P < 0.0005) and 33% (P < 0.05), respectively. (D) Comparison of bleb areas.
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Discussion
There is mounting evidence that the MRTF/SRF pathway plays an important role in fibrosis as many key genes 
involved in fibrosis are also SRF target genes, including ACTA2 and CTGF7, 35, 36, and MRTF knockout models 
have shown reduced fibrosis in the heart36, lungs37, kidney38, and blood vessels9. Earlier MRTF-A inhibitors have 
proved efficient in targeting Rho-mediated MRTF/SRF signalling14, with a second generation inhibitor, CCG-
203971, showing lower toxicity and increased efficiency16, 17. We show here that the novel MRTF/SRF pathway 
inhibitor CCG-222740 was more potent than the previously described CCG-203971 at decreasing MRTF/SRF 
target gene expression in human conjunctival fibroblasts, specifically expression of αSMA, a classical hallmark of 
fibrosis39–41, both in vitro and in vivo. Inhibition of MRTF/SRF signalling also prevented scar tissue formation in 
target tissues in vivo. MRTF/SRF pathway inhibition was not appreciably cytotoxic, but was as effective as tradi-
tional agents such as MMC at preventing scar tissue formation in a preclinical rabbit model of fibrosis.
Figure 5. Local delivery of CCG-222740 or CCG-203971 prevents scar tissue formation. The white filtration 
tube was used as landmark, and tissue was sectioned through the bleb area on a plane 2 mm from the tube and 
stained (black line). The left operated eyes were compared to the right non-operated eyes, which were used as 
controls for the appearance of normal conjunctival tissue. Scale bar = 100 μm; c, conjunctiva, b, subconjunctival 
space, s, sclera. Analysis was performed using the mean results in each treatment group. Statistically significant 
differences are expressed as *P < 0.05; **P < 0.01. (A,E) Picrosirius red; (B,F) H&E; (C,G) αSMA; (D,H) 
Gomori’s trichrome stain for extracellular matrix and collagen.
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Previous in vivo studies using the MRTF-A/SRF inhibitors CCG-142315 and CCG-20397116, 17, established 
their anti-fibrotic potential in mouse models of vascular9, skin10, and lung fibrosis11. In all three studies, the 
inhibitors were injected intraperitoneally in mice, and were found to decrease fibrosis in blood vessels, skin, or 
lungs. The peak concentrations of inhibitor resulting from systemic injections in these studies were in a similar 
range to what we injected locally to the conjunctiva. Systemic delivery of compounds inhibiting the MRTF/SRF 
pathway nevertheless has potentially deleterious side effects in the body. MRTF plays a key role in vessel growth 
and maturation42, and endothelial depletion of murine MRTF/SRF can cause intracerebral haemorrhagic stroke43. 
Endothelial MRTF/SRF ablation can also lead to incomplete formation of the retinal vasculature in the eye44, and 
both SRF deletion or treatment with CCG-1423 significantly worsened denervation-induced muscle atrophy in 
mice45.
Given these concerns, we note that the eye has the advantage of being a closed compartment where 
small-molecule agents can be injected close to the target tissues, with minimal risks of systemic side effects46, 47. 
Local delivery of CCG-222740 and CCG-203971 did not cause any local or systemic adverse side effects in our 
study with very low drug levels measured in the aqueous, vitreous, and serum. This may reflect a rapid drug 
clearance, despite the blood-ocular barrier48, facilitated by the small drug quantities used as part of the targeted 
delivery. The blood-aqueous barrier and the blood-retina barrier both consist of cells joined together by tight 
junctions and maintain the eye as a privileged site for normal visual function48.
Mitomycin-C (MMC) is used to modulate wound healing in glaucoma surgery, to prevent recurrence in 
pterygium surgery, to prevent corneal haze in refractive surgery, and to treat conjunctival neoplasia49. However, 
MMC acts by inhibiting DNA synthesis and causes widespread apoptosis3, and serious vision-threatening side 
effects have been associated with its use, including hypotonous maculopathy5, severe infection6, corneal melt-
ing and perforation50, and scleral calcification51. In contrast, repeated administration of CCG-222740 or CCG-
203971, which are relatively non-toxic10, was effective at reducing fibrosis and unlike MMC did not affect cell 
proliferation or induce apoptosis in the conjunctival epithelium. However, these compounds require a repeated 
Figure 6. CCG-222740 and CCG-203971 preserve the conjunctival epithelium and do not cause any local 
toxicity. Sections were cut and stained as in Fig. 5. (A) H&E and Picrosirius red staining. Arrows indicate 
disruption of epithelium with MMC treatment. Scale bar = 100 μm. (B) Ki67 staining for proliferation. (C) 
Conjunctival vascularity as an indicator of local toxicity.
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dosing regimen to be effective, precluding their use in a clinical setting. Development of sustained-release formu-
lations, or compounds with better pharmacokinetics, will thus be needed to take advantage of local drug delivery 
for successful translation to benefit patient care. In the absence of inhibitors with more favourable pharmacoki-
netics, future work will aim to successfully incorporate the current inhibitors into potential slow-release formu-
lations, such as ocular tablet32, 52, microspheres53, microfilms54, or ocular implants55, for sustained drug delivery 
to the eye and other tissues.
While the effects of CCG-222740 and CCG-203971 are readily understood by their effect on MRTF/SRF 
signalling, the molecular target for these remains to be definitively established. There are currently two proposed 
mechanisms of action for the parent MRTF/SRF pathway inhibitor CCG-1423. Lundquist et al. have reported 
that CCG-1423 increases nuclear G-actin and decreases MRTF-A in the nucleus through inhibition of MICAL-
2, a member of the MICAL family of actin-binding mono-oxygenases18. On the other hand, Hayashi et al. have 
reported that CCG-1423 acts directly on MRTF and other RPEL-family of proteins to prevent the nuclear import 
of MRTF-A19. In this regard, identifying the molecular targets of the new CCG-222740 described here could 
provide significant insight into the design of future therapeutic strategies. While CCG-222740 was clearly more 
potent than CCG-203971 in the contractility and gene transcription assays, the two compounds were equally effi-
cacious in SRF reporter assays in transfected cells. The reasons for this remain unclear: it may reflect differential 
effects of the transfection protocol on subsequent cellular uptake of the two compounds, different sensitivities of 
authentic SRF genes to variations in inhibitor efficacy, or differential effects of the inhibitors on non-SRF targets.
This study provides proof-of-concept that local delivery of MRTF/SRF pathway inhibitors decreases scar tissue 
formation in a preclinical model of fibrosis. In particular, a novel MRTF/SRF pathway inhibitor, CCG-222740, 
is as effective as MMC in prolonging the long-term success of surgery but without detectable local or systemic 
adverse side effects. Although the optimum dose and drug delivery method of the inhibitor have yet to be deter-
mined, our results show that CCG-222740 could be delivered locally to target tissues to decrease scarring and 
fibrosis. Modulating the MRTF/SRF pathway using CCG-222740 thus represents a new avenue for regulating 
wound healing and for preventing post-surgical scarring in the eye and other tissues, with potential as a new and 
safe anti-fibrotic treatment in the future.
Methods
Patient sample and Animal use. Human conjunctival fibroblasts were isolated from donor eyes in the 
eye bank and informed consent was obtained from all subjects. All experimental protocols were approved by the 
institutional approval committee at the University College London Institute of Ophthalmology, and all the meth-
ods were carried out in accordance with the approved guidelines56. All animal procedures were also performed in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and all animal 
experimental protocols were approved by the Home Office UK (Project licence PPL 70/8074: maximising the 
success and effects of glaucoma surgery).
Reagents and compounds. CCG-222740 and CCG-203971 were synthesised and characterised in the 
Vahlteich Medicinal Chemistry Core at the University of Michigan. Samples were >95% pure by high perfor-
mance liquid chromatography (HPLC).
Primary cell culture. We isolated primary cultures of human conjunctival fibroblasts from human con-
junctival tissues. We also cultured rabbit conjunctival fibroblasts from New Zealand white rabbit conjunctival 
tissues. The tissues were mechanically dispersed and the tissue fragments were placed in tissue culture dishes 
in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) with 10% fetal calf bovine serum (FBS), 100 U/ml 
penicillin, 100 mg/ml streptomycin, and 2 nM L-glutamine, in tissue culture incubators with 5% CO2 and 95% 
humidity. Fibroblasts between passages 2–8 were used in the experiments.
Collagen contraction assay. We screened two candidate MRTF/SRF pathway inhibitors, CCG-222740 and 
CCG-203971, using detached three-dimensional fibroblast-populated collagen gels56, 57. Human or rabbit conjunc-
tival fibroblasts were seeded in a collagen Type I matrix (First Link UK Ltd, Birmingham, UK) at a concentration of 
0.7 × 104 cells/ml. The fibroblast-populated collagen gel mixture was cast into the wells of MatTek dishes (MatTek 
Corp, MI, USA). The gels were detached from the edges of the well and 2 ml of growth medium were added to 
each well with 5, 25, 50, 75, or 100 μM of CCG-222740 or CCG-203971 or 0.1% DMSO control. Digital photo-
graphs were obtained daily and lattice areas were measured using Image J software (http://rsb.info.nih.gov/ij/). 
The gel size at day 7 was assessed as a percentage of lattice area on day 0. Each experiment was performed as trip-
licate gels per condition and the experiment was repeated on three separate days.
SRF reporter gene assay. Human or rabbit conjunctival fibroblasts were plated at 2 × 104 cells/well in 
24-well plates (Falcon, Fisher Scientific) for transient transfection. Conjunctival fibroblasts in each well were 
co-transfected using 2.5 μl Lipofectamine LTX and 0.5 μl Plus reagent (Invitrogen) with 8 ng of SRF reporter plas-
mid 3DA.Luc, 20 ng of pTK-Renilla-Luc and 172 ng of pEF in OptiMEM (Gibco)58. After 2 hours of transfection, 
fibroblasts were allowed to recover in DMEM +10% FCS overnight.
HEK293T cells were plated at 2 × 104 cells/well in 96-well plates (Falcon, Fisher Scientific) and co-transfected 
using Lipofectamine 2000 (Invitrogen) with 4 ng of SRF reporter plasmid SRE.L. luciferase15, and 2 ng of either 
Gα12Q231L or pcDNA3.1/Zeo(−) diluted in Opti-MEM (Gibco). After 5 hours of transfection, cells were allowed 
to recover in DMEM +10% FCS overnight.
The next day, the cells were serum starved in DMEM +0.3% FCS and 5, 25, 50, or 100 μM of CCG-222740 or 
CCG-203971 or 0.1% DMSO control for 24 hours. The cells were then lysed and luciferase levels were measured 
using a Luciferase Assay System (Promega), according to the manufacturer’s instructions. Each experiment was 
carried out in triplicates for each condition and the experiment was repeated three times.
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Cell viability assay. Human conjunctival fibroblasts were plated at 6.25 × 103 cells/well in 96-well plates 
(Falcon, Fisher Scientific), and treated with 1, 3, 10, 30 or 100 μM of CCG-222740 or CCG-203971 or 0.1% DMSO 
control for 24 hours. 20 μl of CellTiter 96 Aqueous one solution (Promega) were then added to each well contain-
ing the samples in 100 μl of culture medium. The plate was incubated for 1 hour at 37 °C and the absorbance was 
measured at 490 nm on a SpectraMax Plus 384 spectrophotometer (Molecular Devices, California, USA). Each 
experiment was carried out in triplicates for each condition and the experiment was repeated three times.
HEK293T cells were plated at 2 × 104 cells/well in 96-well plates (Falcon, Fisher Scientific), and treated with 
0.1, 0.3, 1, 3, 10, 30 or 100 μM of CCG-222740 or CCG-203971 or 0.1% DMSO control for 24 hours. Cell viability 
was measured using WST-1 reagent (10 μl/well, Roche) and read at 450 nm on a SpectraMax Plus 384 spectropho-
tometer (Molecular Devices, California, USA). The experiment was repeated three times.
Real-Time quantitative PCR. Human or rabbit conjunctival fibroblasts were plated at 1 × 105 cells/well in 
6-well plates (Falcon, Fisher Scientific). The next day, the fibroblasts were treated with 5, 10, 25, or 50 μM of CCG-
222740 or CCG-203971 or 0.1% DMSO control in DMEM +10% FCS for 24 hours. The fibroblasts were then lysed 
for RNA extraction using the Sigma RNA isolation kit (Sigma-Aldrich), according to the manufacturer’s instruc-
tions. Reverse transcription was carried out using the Transcriptor First Strand cDNA Synthesis Kit (Roche), 
according to the manufacturer’s instructions. qRT-PCR reactions were performed using SYBR green reagents 
(Life Technologies) on an HT7900 Fast Real-Time PCR system (Applied Biosystems). The human exonic primer 
sequences were: ACTA2, 5′-AATGCAGAAGGAGATCACGC-3′, 3′-TCCTGTTTGCTGATCCACATC-5′; 
CTGF, 5′-CAGAGTGGAGCGCCTGTT-3′, 3′-CTGCAGGAGGCGTTGTCA-5′; GAPDH, 5′-ACGGAT 
TTGGTCGTATTGGGC-3′, 3′-TTGACGGTGCCATGGAATTTG-5′. The rabbit exonic primer sequences were 
ACTA2, 5′- TCCACCGCAAATGCTTCTAAGT-3′, 3′- ATGAGTCAGAGCTTTGGATAGGC-5′; GAPDH, 5′-CGA 
GACACGATGGTGAAGG-3′, 3′-CCAGCATCACCCCACTTGAT-5′. All mRNA values were normalised relative 
to that of GAPDH. Each experiment was carried out in triplicates for each treatment group and the experiment 
was repeated three times.
Alpha smooth muscle actin staining. Human conjunctival fibroblasts were plated on 20 mm glass cov-
erslips at 1 × 105 cells/well in 6-well plates (Falcon, Fisher Scientific). The next day, the fibroblasts were treated 
for 48 hours with 10 or 25 μM of CCG-222740 or CCG-203971 or 0.1% DMSO control in DMEM +10% FCS. 
The samples were fixed in 4% paraformaldehyde for 10 minutes, washed three times in PBS, and permeabilised in 
PBS 0.2% TX-100 (Triton X-100, Sigma) for 20 minutes. The samples were blocked with 5% fetal calf serum/5% 
bovine serum albumin (Sigma) for 1 hour. The samples were incubated overnight with the Cy3-labelled alpha 
smooth muscle actin antibody (1:1000, Sigma) in a wet chamber at 4 °C in the dark. The next day, the samples 
were washed twice in PBS 0.1% TX-100 and incubated with phalloidin (1:200) and DAPI (1:2000) for 1 hour at 
room temperature. The samples were then mounted on slides and imaged using an Upright780 Zeiss LSM confo-
cal microscope. The proportion of fibroblasts with prominent αSMA-positive stress fibres was quantified visually 
from three random fields of view per treatment group in 3 independent experiments.
Western blotting. Human conjunctival fibroblasts were lysed using 2x SDS sample buffer (100 mM Tris 
HCL ph6.8, 4% SDS, 20% glycerol, 200 mM dithiothreitol, 0.2% bromophenol blue). Equal amounts of protein 
were loaded onto and run on 4–12% NuPAGE Bis-Tris protein gels (Novex, Life Technologies). The gels were 
transferred onto nitrocellulose blotting membranes (Amersham, Life Sciences), and blocked in 3% non-fat milk 
in PBST (PBS 0.1% Tween) for 1 hour. The membranes were then incubated overnight at 4 °C in αSMA pri-
mary antibody (1:200, polyclonal rabbit, ab5694, Abcam). The next day, the membranes were washed three times 
for 10 minutes in PBST, and incubated for 1 hour at room temperature in anti-rabbit HRP (1:2500, Dako). The 
membranes were then washed three times for 10 minutes in PBST, treated with ECL solution (Amersham, Life 
sciences) for 5 minutes, and scanned on an Odyssey IR Imager (LI-COR).
Rabbit glaucoma filtration surgery model of scar tissue formation. 24 female New Zealand white 
rabbits (2–2.4 kg, 12—14 weeks, Highgate, UK) underwent experimental glaucoma filtration surgery to the left 
eye under general anaesthesia27, 28. A superonasal fornix-based conjunctival flap was raised behind the limbus and 
a micro-vitreoretinal blade (20 gauge, 0.90 mm, Surgistar USA) was used to make a partial thickness scleral tunnel 
to the corneal stroma. A 22 gauge, 25 mm intravenous cannula was passed through the tunnel and the needle was 
removed once it was visible in the cornea. The cannula was advanced into the mid-pupillary area, trimmed at its 
scleral edge and fixed to the scleral surface using a 10–0 nylon suture (Alcon, USA). The conjunctival incision was 
closed using two interrupted 10–0 nylon sutures. In a randomised, prospective, single-masked observer study, the 
rabbits received either intraoperative 0.2 mg/ml mitomycin-C (MMC) [N = 6], or postoperative subconjunctival 
injections (100 μl) of 100 μM CCG-203971 [N = 6] or 100 μM CCG-222740 [N = 6] or vehicle control [N = 6] 
daily for the first nine days followed by twice weekly for three weeks4, 33. CCG-222740 and CCG-203971 were 
dissolved in 100% DMSO (Sigma, UK) at 10 mM and then diluted to 100 μM with sterile PBS. The same volume 
of DMSO was diluted with PBS for the vehicle control. For the MMC-treated group, a small corneal light shield 
sponge was soaked in 1 ml of 0.2 mg/ml MMC and applied over the conjunctiva for 3 minutes, and the area was 
then thoroughly washed with 50 ml of physiologic balanced salt solution (Alcon Laboratories, Inc., Fort Worth, 
TX). All the postoperative subconjunctival injections were given at the same site by a single-masked researcher.
Post-operative clinical examination. The animals were evaluated twice weekly by a single-masked 
researcher. Bleb width and length were measured using calipers and intraocular pressures (IOP) were meas-
ured using a tonovet (Icare). The primary efficacy end-point was bleb survival as this is indicative of the 
long-term opening of the filtration pathway created during surgery. Bleb failure was defined as the appearance 
of a flat, scarred, and vascularised bleb associated with a deep anterior chamber. IOP survival, defined as when 
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the intraocular pressure remains below the baseline IOP measurement, and bleb area were used as secondary 
end-points. Conjunctival vascularity was graded on a scale of 0 to 3 (0: avascular, 1: normal, 2: hyperaemic, 3: 
very hyperaemic).
Histologic analysis. The animals were sacrificed on day 30 and both eyes were enucleated. The eyes were 
fixed in formalin, embedded in paraffin, and sequential 4 μm tissue sections were cut.
The sections were stained with hematoxylin and eosin (for cellularity and inflammatory cells), Gomori’s tri-
chrome (for collagen), picrosirius red (for degree of fibrosis and collagen deposition), and alpha-smooth mus-
cle actin (αSMA) using a primary monoclonal mouse anti-human αSMA antibody (Clone 1A4; Dako, High 
Wycombe, UK) and a biotinylated secondary antibody (rabbit anti-mouse; Dako). All the left operated eyes were 
compared to the right non-operated eyes that were used as controls for the appearance of normal conjunctival 
tissue. The sections were graded using a modified grading system originally described by Shah et al.34, with a 
scale of −4 to +4 according to the staining intensity. Grades were defined as 0 = same as control eye; 1 = 1–25% 
difference from control eye; 2 = 26–50% difference from control eye; 3 = 51–75% difference from control eye; 
4 = >75% difference from control eye (prefix+, more than; prefix −, less than).
For the Ki67 staining, the sections were dewaxed, rehydrated, and microwaved for 15 minutes in sodium 
citrate buffer (pH 6) for antigen retrieval. After incubating in 1.6% hydrogen peroxide followed by 10% normal 
horse serum, the sections were incubated in mouse anti-Ki67 (M7248, Dako) diluted 1 in 25 in 1% BSA/PBS for 
1 hour at room temperature. The sections were then incubated in biotinylated horse anti-mouse IgG (Vector) and 
Avidin-Biotin complex (Vector), developed in DAB (Vector), and counterstained in haematoxylin.
Toxicity and Pharmacokinetics. All animals were carefully evaluated for any signs of ocular or systemic 
toxicity during the study. At day 30, 100 µl of aqueous, 1 ml of vitreous, and 1 ml of venous blood were sampled 
on the rabbit eyes receiving CCG-222740 or CCG-203971 or vehicle control. The venous blood samples were left 
to clot for 30 minutes at room temperature, spun at 4000 rpm for 15 minutes at 4 °C, and the serum was collected 
as the supernatant. Samples were extracted in acetonitrile and the levels of CCG-222740 and CCG-203971 were 
measured in the aqueous, vitreous, and serum using liquid chromatography/mass spectrometry (LC/MS) in the 
Metabolomics Core at Michigan State University (East Lansing, MI).
Statistical analysis. Survival analyses for bleb and intraocular pressure were performed using the 
Kaplan-Meier log rank test. All graphs display mean and standard error of the mean (SEM). Statistical analysis 
was performed using the Student’s t-test to calculate statistically significant differences and individual P values. 
Statistically significant differences were expressed as *P < 0.05; **P < 0.01; ***P < 0.001.
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